All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions DRUG UPDATES

AML Types

2018-06-19T15:30:55.000Z

Agnieszka Wierzbowska | EHA 2018| Current and emerging treatment options for elderly AML patients?

By Agnieszka Wierzbowska

Jun 19, 2018

Bookmark this article

At the 23rd Congress of the European Hematology Association, Agnieszka Wierzbowska comments on the emerging treatment for elderly acute myeloid leukemia (AML). Agnieszka discussed a range of studies using venetoclax in the unfit population of elderly AML patients. She concluded that the new combinations of the standard treatment provide a new hope for elderly AML patients.